Análisis de inmunogenicidad y perfil de seguridad de vacunas contra el SARS-CoV-2 en ensayos clínicos de fase I/II / Immunogenicity and safety profile analysis of SARS-CoV-2 vaccines in phase I/II clinical trials

ABSTRACT

The development of an effective vaccine against SARSCoV-2 has turned into a global priority in order to stop the advance of this ongoing COVID-19 pandemic. To date there are 25 candidate vaccines currently in a clinical trial stage, 3 of which have been subjected to phase I/II preliminary reports (ChAdOx1 nCoV-19, BNT162b1 and mRNA-1273). These vaccines have demonstrated to elicit robust cellular and humoral immune responses when compared to convalescent patients serum samples and have shown an acceptable safety profile with no reported severe side effects. Here we discuss the reported evidence regarding these vaccines.